Objective and Methods Idiopathic interstitial pneumonias (IIPs) 
Introduction
Idiopathic interstitial pneumonias (IIPs) appear to be associated with lung carcinogenesis. In particular, the incidence of lung cancer in patients with idiopathic pulmonary fibrosis (IPF) is higher than in the general population, with relative risks reported to be from 7 to 14 (1) (2) (3) (4) (5) . Kawasaki et al (6) reported that IPF was found in 7.5% of surgically-resected lung cancer cases. Recently, it has been recognized that IPF could lead to the development of lung cancer (3) 
, although the etiology has not yet been elucidated. IIPs result in chronic injury to the bronchiolar and alveolar epithelia and are characterized by fibrosis and remodeling of the peripheral lung. This chronic inflammation may increase the risk of development of cancer through accumulated DNA damage (7). It has been reported that in the bronchiolar and alveolar epithelia within the honeycomb-like lesions of patients with IPF and/or lung cancer several tumor suppressor genes such as p53, K-ras, and FHIT (fragile histidine triad)
are frequently found to be mutated or deleted (7) (8) (9) (10) (11) (12) . Those (16) (17) (18) . 
The induction of acute exacerbation by anticancer agents has attracted attention following reports in Japan of interstitial lung disease (ILD) developing after treatment with gefitinib, an epithelial growth factor receptor (EGFR) tyrosine

Results
Characteristics and clinical features of patients
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Anticancer treatments and the development of acute exacerbation of IIPs
The anticancer treatment modalities that had been administered to the study patients are shown in IIPs, idiopathic interstitial pneumonias; AE, acute exacerbation; BSC, best supportive care § including patients who received multimodality treatment † Two patients had 2 episodes of acute exacerbation T a b l e 7 . Co mp a r i s o n o f L a b o r a t o r y Da t a b e f o r e I n i t i a l Ch e mo t h e r a p y f o r L u n g Ca n c e r b (24) , and 7 out of 45 patients (15.6%) by Hanibuchi (25) . In this present study, the incidence of acute exacerbation and acute exacerbation-related mortality were 22 (33, 34) . In addition, Anscher et al reported that high serum concentrations of transforming growth factor-beta were associated with an increased incidence of pulmonary fibrosis after chemotherapy (35) . In the present study, a high serum concentration of CRP before chemotherapy was associated with a significant likelihood of a patient developing, acute exacerbation. 
Efficacy of the initial chemotherapy
In 20 patients with SCLC, chemotherapy was administered to 13 and chemoradiotherapy was performed in 5; only 2 patients received BSC. On the other hand, in the 100 patients with NSCLC, radical surgery was performed in 35,
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Chemotherapy regimens and the risk of developing acute exacerbation of IIPs
One of the strategies for reducing the incidence of acute exacerbation of IIPs is to identify appropriate anticancer agents for the treatment of patients with IIPs. The incidence rate of acute exacerbation of IIPs and the response rates to various chemotherapeutic treatment regimens are shown in
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Risk factors of chemotherapy-induced acute exacerbation of IIPs
In the selection of patients, to exclude those at high-risk for acute exacerbation of IIPs can be recommended to improve treatment safety. We compared various pretreatment examination data (taken before administration of initial chemotherapy) between patients who did and did not subsequently develop acute exacerbation (
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